about
No fate but what we make: a case of full recovery after out-of-hospital cardiac arrest.Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Cholesterol pericarditis--relapsing pericardial effusion in a patient with rheumatoid arthritis.Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomesCardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.Anemia and iron deficiency in heart failure.New approaches for improving cardiovascular risk assessment.Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.[Infectious endocarditis caused by Q fever. Apropos of a clinical case]Integration of Different Risk Assessment Tools to Improve Stratification of Patients with Coronary Artery Disease.Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.Diagnosis of myocardial infarction using the new universal definition: is it enough for risk stratification and guiding decision for revascularization?[Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation].Apical ballooning syndrome during diagnostic coronary angiography.Serologic markers for cytomegalovirus in acute coronary syndromes.Glucose metabolism in non-diabetic patients with stable coronary artery disease.Metabolic score--a simple risk marker in non-ST elevation acute coronary syndromes.[Acute myocardial infarction complicated by cardiogenic shock: what changed over a 10-year time span?].Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years.TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications.Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.Early reperfusion in myocardial infarction requires widespread access to prehospital emergency care.Improvement of CVD risk assessment tools' performance through innovative patients' grouping strategies.Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.Coronary sinus pacing in a patient with a tricuspid prosthesis.For the improvement of Heart Failure treatment in Portugal - Consensus statement.Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.National Registry of Acute Coronary Syndromes: results of the hospital phase in 2002.Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models.[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.Cholesterol is Inefficiently Converted to Cholesteryl Esters in the Blood of Cardiovascular Disease PatientsFusion of risk assessment models with application to coronary artery disease patients[Holter electrocardiography en pediatric cardiology: preliminary experience][The analysis of negative studies in myocardial perfusion scintigraphy][Stress echocardiography with dipyridamole/atropine in the detection of myocardial ischemia: a comparison with thallium-201 scintigraphy and an angiographic correlation][The 3-year prognosis of patients with suspected coronary disease and a normal myocardial scintigraphy with thallium-dipyridamole]
P50
Q33554651-9BAB4616-F894-4AF2-ABB3-B22096C961DBQ35975334-D4C10CA9-14D8-417C-A84A-F6A6432B4EA2Q36206107-40987E72-2376-4F37-81B6-B48288A1509AQ37619780-06ADBD2A-ADA3-4C3B-A0FE-85339780BF0BQ37628639-660DD72C-8EBB-4735-BF1D-E149C88994E3Q38161657-E6D20D41-BEDB-4E32-8C38-C8696774A400Q40135622-9E05BBBF-E236-4637-B7E6-84D5F7F8073BQ40617314-67CE2221-3D82-4648-B3E8-BB267023C47FQ40661432-D9C23AC5-82AC-4538-889C-A1C32938DB01Q40690968-4BE59CAC-DCE7-42D1-85FB-433C318F346DQ41610947-D7C7ABFE-CE53-4D66-A70D-305A81AA745FQ42830698-325D5FFC-FB9C-4902-A614-192A4CD801C1Q42855772-987C98D8-A85B-4A79-A599-20DABCDE43F3Q43560837-2D3CDC71-5975-4AAC-9649-14A0295E6900Q43590301-B0E43B55-A6E1-402F-AC90-DD91118459A1Q44166443-AEDD4CCA-6D01-4FEB-95BD-5C2B00D4D60FQ44214411-1CB47F34-89CA-4A42-AE6B-72034FBC2D0CQ44790398-D9F019D5-6516-4B53-A0A2-7C8A6C4F42CFQ46095349-5CD9D335-7584-40E9-A6DA-F01CD1A8C71BQ46136203-E880B184-1CFE-4D6B-BCA6-C3F8E7232DC5Q46375283-B5CBB911-DCCA-4CD9-AD75-58736ADEE789Q46453932-8FC702BA-DA66-4E4A-98D8-2197BCE6021AQ47900509-E4D84A03-E20A-46EF-A00B-7C84E22E03B5Q48624138-4D46787F-6C56-4E0C-9EFD-AD6F5FD69150Q50150654-ABB1D6EE-FD2D-49F5-9D46-986A4714B754Q50762150-C1146E96-8A18-40D3-9F07-89A368C5A1A7Q51219498-237D4F49-EF2F-4553-88D5-64F84B6D81DFQ51275226-C4686213-F44A-40D9-9A04-EEBC0FE7AC03Q52799629-BF742EBA-EFA1-4D53-A886-7F4C55DA3F73Q53274021-237505E6-F170-4AFA-B909-FCE86FD78BBFQ53279643-3E2B9FCA-5778-4F3F-ADED-FC492C313485Q53442916-CA4ED858-EDA0-4C9F-837F-943C78BFB0D8Q53629661-D7673852-DC1D-4F47-95B0-AAEC13F1665CQ54458532-2D8466BD-E9FF-4E1F-B6C9-0D5ED2AAE8F1Q57041939-045E6F8A-71E3-4123-9843-2E08F3B2EBE1Q59187981-833E4FC1-B484-4DA4-9804-51C224693AF2Q64930608-F6DAE83E-6D49-47FF-B2C4-B58047FFC023Q70836215-46484276-4C84-400B-82CB-413F078F7331Q70836290-0DA98650-2E3F-4279-A66A-AA2E6E516CCCQ71087101-5C6A7A60-0DEA-45C9-AF3D-73C872FE97DC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jorge Ferreira
@ast
Jorge Ferreira
@en
Jorge Ferreira
@es
Jorge Ferreira
@sl
type
label
Jorge Ferreira
@ast
Jorge Ferreira
@en
Jorge Ferreira
@es
Jorge Ferreira
@sl
prefLabel
Jorge Ferreira
@ast
Jorge Ferreira
@en
Jorge Ferreira
@es
Jorge Ferreira
@sl
P106
P21
P31
P496
0000-0002-5592-6199